Investigational drug stops toxic proteins tied to neurodegenerative diseases
(University of Pennsylvania School of Medicine) An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic. Results were published in Science Translational Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: ALS | Brain | Dementia | International Medicine & Public Health | Neurology | Neuroscience | Science | Study | Toxicology | University of Pennsylvania